![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AKS-452 is a protein subunit vaccine that is in Phase II testing at the University Medical Center Groningen (UMCG), one of the largest hospitals in the Netherlands.
Lead Product(s): Engineered SARS-CoV-2-RBD-Fc Fusion Protein Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: AKS-452
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Akston Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 21, 2021